Adtran and Sonic Fiber Internet partner to deliver 50G PON connectivity across California
1.11.2024 15:00:00 EET | Business Wire | Press release
Adtran today announced its strategic collaboration with Sonic Fiber Internet to bring 50Gbit/s passive optical network (50G PON) connectivity to California. The partnership is a proactive step to ensure Sonic continues to deliver ultra-fast broadband services that meet the growing demand for higher capacity and faster speeds across the US. By leveraging Adtran’s 50G PON technology, Sonic aims to lead the industry in connectivity standards for both residential and business customers, enabling a range of applications from smart home integration and advanced entertainment streaming to frictionless remote work and high-speed business connectivity. The technology coexists with GPON and XGS-PON, providing a seamless and cost-efficient upgrade path with no service disruption, while future-proofing the network and ensuring scalability for evolving digital needs. It also supports Combo PON setups, integrating multiple generations of fiber technology to fully maximize deployment flexibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101302692/en/
Adtran’s 50G PON technology will help Sonic set a new standard for ultra-fast connectivity in the US. (Photo: Business Wire)
“Our partnership with Adtran marks a major milestone in the evolution of ultra-fast connectivity in California. By developing the state’s first 50G PON network, we’re laying the foundation to meet the rapidly growing demands of emerging technologies and data-intensive applications, as well as supporting emerging standards like Wi-Fi 7, Wi-Fi 8 and beyond,” said Stephen Bradley, VP of sales and marketing at Sonic Fiber Internet. “This collaboration keeps Sonic ahead of industry trends and consumer needs, ensuring our customers always receive the fastest and most reliable internet experience available at the lowest price. It sets the stage for a new era of connectivity, empowering our customers to embrace the future with confidence.”
Adtran and Sonic are joining forces to advance state-of-the-art FTTX connectivity that delivers symmetrical speeds of 50Gbit/s, ensuring bandwidth capacity for even the most demanding applications. Adtran and Sonic’s 50G PON partnership will support targeted rollouts in high-demand areas while providing cost-effective scalability for future growth. The new technology will also help reduce operational costs and environmental impact, making it a sustainable choice for network evolution.
“With their forward-thinking approach to advancing high-speed broadband, it’s no surprise that Sonic is taking a leading role with 50G PON. Our partnership will drive future-ready infrastructure to meet both today’s and tomorrow’s connectivity demands, further strengthening Sonic’s position as a pioneer in ultra-fast, highly reliable internet services,” commented Christoph Glingener, CTO of Adtran. “By integrating with existing fiber networks, 50G PON enables incremental upgrades that minimize disruption while allowing Sonic to stay ahead of market trends. This approach supports a variety of use cases, from enhancing connectivity in homes and high-density residential areas to powering enterprise campuses and public Wi-Fi expansion. It also future-proofs the network for emerging Wi-Fi standards and smart city infrastructure, driving down costs and accelerating widespread adoption.”
For more information on Adtran and Sonic’s 50G PON plans, please register for a joint webinar to be held on November 14.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101302692/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom